A detailed history of Lindbrook Capital, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Lindbrook Capital, LLC holds 151 shares of MYGN stock, worth $2,038. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151
Previous 148 2.03%
Holding current value
$2,038
Previous $3,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$23.97 - $28.6 $71 - $85
3 Added 2.03%
151 $4,000
Q2 2024

Jul 31, 2024

BUY
$17.98 - $25.47 $809 - $1,146
45 Added 43.69%
148 $3,000
Q4 2023

Jan 31, 2024

BUY
$13.91 - $21.32 $1,432 - $2,195
103 New
103 $1,000
Q2 2023

Jul 28, 2023

SELL
$17.56 - $23.76 $1,000 - $1,354
-57 Reduced 77.03%
17 $0
Q1 2023

Apr 26, 2023

BUY
$15.26 - $23.75 $1,129 - $1,757
74 New
74 $1,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.09B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.